TY  - JOUR
A1  - Nemes, Karolina
A1  - Johann, Pascal D.
A1  - Steinbügl, Mona
A1  - Gruhle, Miriam
A1  - Bens, Susanne
A1  - Kachanov, Denis
A1  - Teleshova, Margarita
A1  - Hauser, Peter
A1  - Simon, Thorsten
A1  - Tippelt, Stephan
A1  - Eberl, Wolfgang
A1  - Chada, Martin
A1  - Lopez, Vicente Santa-Maria
A1  - Grigull, Lorenz
A1  - Hernáiz-Driever, Pablo
A1  - Eyrich, Matthias
A1  - Pears, Jane
A1  - Milde, Till
A1  - Reinhard, Harald
A1  - Leipold, Alfred
A1  - van de Wetering, Marianne
A1  - Gil-da-Costa, Maria João
A1  - Ebetsberger-Dachs, Georg
A1  - Kerl, Kornelius
A1  - Lemmer, Andreas
A1  - Boztug, Heidrun
A1  - Furtwängler, Rhoikos
A1  - Kordes, Uwe
A1  - Vokuhl, Christian
A1  - Hasselblatt, Martin
A1  - Bison, Brigitte
A1  - Kröncke, Thomas
A1  - Melchior, Patrick
A1  - Timmermann, Beate
A1  - Gerss, Joachim
A1  - Siebert, Reiner
A1  - Frühwald, Michael C.
T1  - Infants and newborns with atypical teratoid rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors (eMRT) in the EU-RHAB registry: a unique and challenging population
JF  - Cancers
N2  - Introduction: Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity of treatment. Information on prognostic factors, genetics, toxicity of treatment and long-term outcomes is sparse. Methods: Clinical, genetic, and treatment data of 100 patients (aged below 6 months at diagnosis) from 13 European countries were analyzed (2005–2020). Tumors and matching blood samples were examined for SMARCB1 mutations using FISH, MLPA and Sanger sequencing. DNA methylation subgroups (ATRT-TYR, ATRT-SHH, and ATRT-MYC) were determined using 450 k / 850 k-profiling. Results: A total of 45 patients presented with ATRT, 29 with extracranial, extrarenal (eMRT) and 9 with renal rhabdoid tumors (RTK). Seventeen patients demonstrated synchronous tumors (SYN). Metastases (M+) were present in 27% (26/97) at diagnosis. A germline mutation (GLM) was detected in 55% (47/86). DNA methylation subgrouping was available in 50% (31 / 62) with ATRT or SYN; for eMRT, methylation-based subgrouping was not performed. The 5-year overall (OS) and event free survival (EFS) rates were 23.5 ± 4.6% and 19 ± 4.1%, respectively. Male sex (11 ± 5% vs. 35.8 ± 7.4%), M+ stage (6.1 ± 5.4% vs. 36.2 ± 7.4%), presence of SYN (7.1 ± 6.9% vs. 26.6 ± 5.3%) and GLM (7.7 ± 4.2% vs. 45.7 ± 8.6%) were significant prognostic factors for 5-year OS. Molecular subgrouping and survival analyses confirm a previously described survival advantage for ATRT-TYR. In an adjusted multivariate model, clinical factors that favorably influence the prognosis were female sex, localized stage, absence of a GLM and maintenance therapy. Conclusions: In this cohort of homogenously treated infants with MRT, significant predictors of outcome were sex, M-stage, GLM and maintenance therapy. We confirm the need to stratify which patient groups benefit from multimodal treatment, and which need novel therapeutic strategies. Biomarker-driven tailored trials may be a key option.
KW  - atypical teratoid rhabdoid tumors
KW  - extracranial malignant rhabdoid tumor
KW  - RTPS1
KW  - RTPS2
KW  - germline mutation
KW  - EU-RHAB registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270730
SN  - 2072-6694
VL  - 14
IS  - 9
ER  - 
TY  - JOUR
A1  - Meir, Michael
A1  - Maurus, Katja
A1  - Kuper, Jochen
A1  - Hankir, Mohammed
A1  - Wardelmann, Eva
A1  - Rosenwald, Andreas
A1  - Germer, Christoph-Thomas
A1  - Wiegering, Armin
T1  - The novel KIT exon 11 germline mutation K558N is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development
JF  - Genes, Chromosomes & Cancer
N2  - Familial gastrointestinal stromal tumors (GIST) are dominant genetic disorders that are caused by germline mutations of the type III receptor tyrosine kinase KIT. While sporadic mutations are frequently found in mastocytosis and GISTs, germline mutations of KIT have only been described in 39 families until now. We detected a novel germline mutation of KIT in exon 11 (p.Lys-558-Asn; K558N) in a patient from a kindred with several GISTs harboring different secondary somatic KIT mutations. Structural analysis suggests that the primary germline mutation alone is not sufficient to release the autoinhibitory region of KIT located in the transmembrane domain. Instead, the KIT kinase module becomes constitutively activated when K558N combines with different secondary somatic mutations. The identical germline mutation in combination with an additional somatic KIT mutation was detected in a second patient of the kindred with seminoma while a third patient within the family had a cutaneous mastocytosis. These findings suggest that the K558N mutation interferes with the juxtamembranous part of KIT, since seminoma and mastocystosis are usually not associated with exon 11 mutations.
KW  - germline mutation
KW  - GIST
KW  - KIT
KW  - mastocytosis
KW  - seminoma
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-257476
VL  - 60
IS  - 12
ER  -